Abstract | BACKGROUND: METHODS: RESULTS:
Mesothelioma and ovarian cancer were generally more drug sensitive than CRC, appendix cancer and PMP. Oxaliplatin showed the most favorable ratio between achievable IPC concentration and ex vivo drug sensitivity. Drug sensitivity in CRC varied considerably between individual samples. Ex vivo drug sensitivity did not obviously correlate to time-to-progression ( TTP) in individual patients. CONCLUSIONS:
Drug-sensitivity varies considerably between PC diagnoses and individual patients arguing for individualized therapy in IPC rather than standard diagnosis-specific therapy. However, in the current paradigm of treatment according to diagnosis, oxaliplatin is seemingly the preferred drug for IPC from a drug sensitivity and concentration perspective. In the CRC subset, analysis of correlation between ex vivo drug sensitivity and TTP was inconclusive due to the heterogeneous nature of the data.
|
Authors | Peter H Cashin, Haile Mahteme, Wilhelm Graf, Henning Karlsson, Rolf Larsson, Peter Nygren |
Journal | BMC cancer
(BMC Cancer)
Vol. 13
Pg. 435
(Sep 24 2013)
ISSN: 1471-2407 [Electronic] England |
PMID | 24063788
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Chemotherapy, Adjuvant
- Colorectal Neoplasms
(drug therapy, mortality, pathology, surgery)
- Female
- Humans
- Infusions, Parenteral
- Inhibitory Concentration 50
- Male
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Metastasis
- Neoplasm Staging
- Peritoneal Neoplasms
(drug therapy, mortality, secondary, surgery)
|